ERC-1671
- Generic Name
- ERC-1671
- Drug Type
- Biotech
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Phase 2
Not yet recruiting
- Conditions
- Glioma, Malignant
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 28
- Registration Number
- NCT05366062
- Locations
- 🇹ðŸ‡
Bumrungrad International Hospital, Bangkok, Vadhana, Thailand
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Phase 2
Active, not recruiting
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Drug: Oral Control (Sucrose pill)Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))Drug: Bevacizumab/Bevacizumab Biosimilar
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT01903330
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of California, Irvine, Orange, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath